Literature DB >> 35430328

Effect of Aspirin on CKD Progression in Older Adults: Secondary Analysis From the ASPREE Randomized Clinical Trial.

Kevan R Polkinghorne1, James B Wetmore2, Le Thi Phuong Thao3, Rory Wolfe3, Robyn L Woods3, Michael E Ernst4, Mark R Nelson5, Christopher M Reid6, Raj C Shah7, John J McNeil3, Anne M Murray8.   

Abstract

Entities:  

Year:  2022        PMID: 35430328      PMCID: PMC9562592          DOI: 10.1053/j.ajkd.2022.02.019

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   11.072


× No keyword cloud information.
  8 in total

1.  Joint modelling of longitudinal measurements and event time data.

Authors:  R Henderson; P Diggle; A Dobson
Journal:  Biostatistics       Date:  2000-12       Impact factor: 5.899

2.  AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association.

Authors:  Sidney C Smith; Emelia J Benjamin; Robert O Bonow; Lynne T Braun; Mark A Creager; Barry A Franklin; Raymond J Gibbons; Scott M Grundy; Loren F Hiratzka; Daniel W Jones; Donald M Lloyd-Jones; Margo Minissian; Lori Mosca; Eric D Peterson; Ralph L Sacco; John Spertus; James H Stein; Kathryn A Taubert
Journal:  J Am Coll Cardiol       Date:  2011-11-03       Impact factor: 24.094

3.  Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial.

Authors: 
Journal:  Contemp Clin Trials       Date:  2013-10-07       Impact factor: 2.226

4.  Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renaL disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design.

Authors:  Francesco Violi; Giovanni Targher; Annarita Vestri; Roberto Carnevale; Maurizio Averna; Alessio Farcomeni; Andrea Lenzi; Francesco Angelico; Francesco Cipollone; Daniele Pastori
Journal:  Am Heart J       Date:  2017-04-18       Impact factor: 4.749

5.  The aspirin in reducing events in the elderly trial: Statistical analysis plan.

Authors:  Rory Wolfe; Anne M Murray; Robyn L Woods; Brenda Kirpach; David Gilbertson; Raj C Shah; Mark R Nelson; Christopher M Reid; Michael E Ernst; Jessica Lockery; Geoffrey A Donnan; Jeff Williamson; John J McNeil
Journal:  Int J Stroke       Date:  2017-11-07       Impact factor: 5.266

6.  Physiologic and pathophysiologic roles of cyclooxygenase-2 in the kidney.

Authors:  Raymond C Harris
Journal:  Trans Am Clin Climatol Assoc       Date:  2013

7.  Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.

Authors:  John J McNeil; Rory Wolfe; Robyn L Woods; Andrew M Tonkin; Geoffrey A Donnan; Mark R Nelson; Christopher M Reid; Jessica E Lockery; Brenda Kirpach; Elsdon Storey; Raj C Shah; Jeff D Williamson; Karen L Margolis; Michael E Ernst; Walter P Abhayaratna; Nigel Stocks; Sharyn M Fitzgerald; Suzanne G Orchard; Ruth E Trevaks; Lawrence J Beilin; Colin I Johnston; Joanne Ryan; Barbara Radziszewska; Michael Jelinek; Mobin Malik; Charles B Eaton; Donna Brauer; Geoff Cloud; Erica M Wood; Suzanne E Mahady; Suzanne Satterfield; Richard Grimm; Anne M Murray
Journal:  N Engl J Med       Date:  2018-09-16       Impact factor: 91.245

8.  Effect of Aspirin on Disability-free Survival in the Healthy Elderly.

Authors:  John J McNeil; Robyn L Woods; Mark R Nelson; Christopher M Reid; Brenda Kirpach; Rory Wolfe; Elsdon Storey; Raj C Shah; Jessica E Lockery; Andrew M Tonkin; Anne B Newman; Jeff D Williamson; Karen L Margolis; Michael E Ernst; Walter P Abhayaratna; Nigel Stocks; Sharyn M Fitzgerald; Suzanne G Orchard; Ruth E Trevaks; Lawrence J Beilin; Geoffrey A Donnan; Peter Gibbs; Colin I Johnston; Joanne Ryan; Barbara Radziszewska; Richard Grimm; Anne M Murray
Journal:  N Engl J Med       Date:  2018-09-16       Impact factor: 91.245

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.